Sarepta Therapeutics announced late Friday evening that it will not comply with the Food and Drug Administration's ...

Sarepta Therapeutics refuses the FDA request to halt its gene therapy shipments following a third patient death, challenging ...

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

The death of a second teenage boy from liver failure caused by a gene therapy from Sarepta Therapeutics has left the Duchenne muscular dystrophy community angry, fearful and divided over whether ...

Like the first death reported in March, Sarepta Therapeutics attributed the fatality to a case of acute liver failure following dosing of the Duchenne muscular dystrophy gene therapy, Elevidys ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age.

Sarepta Therapeutics’ stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug By Ciara Linnane and Eleanor Laise Last Updated: June 21, 2024, 8:05 a.m. ET ...

Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug Provided by Dow Jones Jun 21, 2024, 12:05:00 PM ...

Elevidys is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy ...